The expression of CXCL13 can also be epigenetically tuned by the combined application of the HDACi entinostat with tumor-targeted delivery of interleukin-12 (IL-12), which achieved an elevated level of CXCL13 and CXCL9. Here, CXCL9 is linked to neoplasm.